Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia

Brown G, Albers JJ, Fishers LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289.

The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301.

Yeagle PL. Modulation of membrane function by cholesterol. Biochimie 1991; 73: 1303.

Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425.

Hrboticky N, Tang L, Zimmer B, Lux I, Weber PC. Lovastatin increases arachidonic acid levels and stimulates thromboxane synthesis in human and monocytic cell lines. J Clin Invest 1994; 93: 195.

Hamberg M, Svensson J, Samuelsson B. Thromboxane: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994.

Jones DB, Carter RD, Haitas B, Mann JI. Low phospholipid arachidonic acid values in diabetic platelets. B M J 1983; 286: 173.

Bassi A, Avogaro A, Crepaldi C, Pavan P, Zambon S, Marin R, MacDonald I, Manzato E. Short-term diabetic ketosis alters n-6 polyunsaturated fatty acid content in plasma phospholipids. J Clin Endocrinol Metab 1996; 81: 1650.

Seyberth HW, Oelz O, Kennedy T, Sweetman BJ, Danon A, Frohlich JC, Heimberg M, Oates JA. Increased arachidonate in lipids after administration to man: effects on prostaglandin biosynthesis. Clin Pharmacol Ther 1975; 18: 521.

Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reaction and inflammation. Science 1983; 220: 568.

Barrow SE, Stratton PD, Benjamin N, Brassfield T, Ritter JM. Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolemia at risk of coronary heart disease. Br J Clin Pharmacol 1991; 32: 127.

Milani M, Cimminiello C, Merlo B, Lorena M, Arpaia G, Bonfardeci G. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia. Am J Cardiol 1995; 76: 51A.

Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; II: 757.

Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, Bovbjerg V, Arbogast P, Smith H, Kushi LH, Cobb LA, Copass MK, Psaty BM, Lemaitre R, Retzlaff B, Childs M, Knopp RH. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274: 1363.

Nakamura N, Hamazaki T, Kobayashi M, Ohta M, Okuda K. Effects of eicosapentaenoic acids on remnant-like particles cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus. In Vivo. In press.